[ad_1]
BioNTech bought a factory owned by another pharmaceutical giant, Novartis, in Marburg, Germany, where it is expected to start producing the COVID-19 vaccine in February. It also has agreements with five other factories in Europe, but few can meet the technical requirements of the vaccine.
“In Romania, I am afraid that this type of technology cannot be manufactured. Did you see that bottle? It is a 2 ml bottle, from which 5 doses of vaccine are extracted. It is a technology of division into small fractions and in a bottle, to which, as far as I know, there are no packaging lines in Romania, and maintaining that cold chain at -80 degrees will certainly be very difficult in factories that have other technology. In other words, you have to have a factory built specifically for that kind of technology and formulation to be able to do it. We expected situations such that due to the completely exceptional conditions in which the vaccine must be manufactured, stored, transported and handled, difficulties will appear in the supply chain, “says Dragoş Damian, CEO of Therapy.
For the most important news of the day, broadcast in real time and presented equally, like our Facebook page!
Follow Mediafax on Instagram to see amazing images and stories from around the world!
The content of the website www.mediafax.ro is intended exclusively for your information and personal use. Is prohibited republish the content of this site in the absence of an agreement from MEDIAFAX. To obtain this agreement, contact us at [email protected].
[ad_2]
